首页 > 市场调查报告书 > 製药

药物开发开发业务受託机关

市场调查报告书

商品编码

1524313

体内CRO 市场- 按动物模型（基于囓齿动物、非囓齿动物）、服务（生物分析和DMPK 研究、毒性研究）、药物类型（小分子、大分子）、治疗领域（肿瘤学、心臟病学）、结束-使用，全球预测（2024 - 2032）

In Vivo CRO Market - By Animal Model (Rodent-based, Non-rodent-based), Service (Bioanalysis & DMPK Studies, Toxicity Studies), Drug Type (Small Molecule, Large Molecule), Therapeutic Area (Oncology, Cardiology), End-use, Global Forecast (2024 - 2032)

出版日期: 2024年04月11日 | 出版商:

Global Market Insights Inc. | 英文 272 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在对先进临床前测试和研究服务的需求不断增长的推动下，体内 CRO 市场规模预计在 2024 年至 2032 年期间复合年增长率为 7.8%。随着製药和生物技术公司努力加快药物开发时间并降低成本，他们越来越多地将体内研究外包给专业的 CRO。例如，2023 年 3 月，作为 NVIDIA AI 基金会的一部分，新的 BioNeMo 云服务加速了生命科学研究、药物发现和蛋白质工程。这些组织提供进行复杂动物研究的专业知识，同时确保遵守监管标准并提供高品质的资料。

随着 CRISPR 和先进影像技术等新技术的出现，体内研究变得更加复杂，能够更深入地了解疾病机制和治疗效果。这导致人们越来越依赖拥有必要基础设施和专业知识来进行这些前沿研究的 CRO。精准医学的不断增长趋势也推动了市场的成长，这需要广泛的体内研究来开发标靶疗法。

该行业分为动物模型、服务、药物类型、治疗领域、最终用途和地区。

根据服务，预计到 2032 年，毒性研究领域的体内 CRO 市场规模将大幅增长。 In vivo CRO 提供专业知识和先进设施来进行这些复杂的研究，同时遵守严格的监管指南并提供可靠的资料。

临床药理学领域的体内CRO 市场预计在2024 年至2032 年间将出现显着的复合年增长率。对于确定其安全性、有效性和最佳效果至关重要给药方案。专门从事临床药理学的体内 CRO 提供先进的能力来进行彻底、精确的研究，包括吸收、分布、代谢和排泄 (ADME) 分析。

亚太地区体内 CRO 产业将在 2024 年至 2032 年期间实现令人印象深刻的成长，这归因于製药和生物技术产业的不断扩大，以及研发活动的大量投资的推动。慢性病的盛行率不断上升，加速了对新治疗解决方案的需求，从而推动了对体内 CRO 服务的需求。先进基础设施的存在和创新技术的采用将进一步推动区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 製药和生技公司增加外包
  - 药品审批的严格监管环境
  - 专注于 CRO 的专业服务
  - 个人化医疗需求不断成长
- 产业陷阱与挑战
  - 智慧财产权问题
  - 动物模型使用的严格监管政策
成长潜力分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按动物模型，2021 - 2032

主要趋势
基于囓齿动物
- 大鼠模型
- 小鼠模型
- 其他囓齿动物模型
不囓齿类动物

第 6 章：市场估计与预测：按服务分类，2021 - 2032 年

主要趋势
生物分析和 DMPK 研究
毒性研究
- GLP毒理学研究
- 非 GLP 毒理学研究
其他服务

第 7 章：市场估计与预测：按药物类型，2021 - 2032

主要趋势
小分子药物
大分子药物
- 细胞与基因治疗
- RNA疗法
- 其他大分子药物

第 8 章：市场估计与预测：按治疗领域，2021 - 2032 年

主要趋势
肿瘤学
临床药理学
心臟病学
传染性疾病
神经病学
胃肠病学和肝病学
代谢与内分泌
眼科
自体免疫/发炎状况
其他治疗领域

第 9 章：市场估计与预测：依最终用途，2021 - 2032 年

主要趋势
製药及生物製药公司
医疗器材企业
学术及研究机构

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 11 章：公司简介

Biocytogen
Charles River Laboratories International Inc.
Crown Bioscience
Evotec
GemPharmatech
IQVIA Inc.
Icon Plc
Labcorp Drug Development
Parexel International Corporation
PsychoGenics Inc.
Taconic Biosciences, Inc.

简介目录

Product Code: 8993

In Vivo CRO Market size is estimated to register 7.8% CAGR between 2024-2032, driven by the increasing demand for advanced preclinical testing and research services. As pharmaceutical and biotechnology companies are striving to accelerate drug development timelines and reduce costs, they are increasingly outsourcing their in vivo studies to specialized CROs. For instance, in March 2023, as part of NVIDIA AI Foundations, the new BioNeMo Cloud Service accelerated life sciences research, drug discovery, and protein engineering. These organizations offer expertise in conducting complex animal studies while ensuring compliance with regulatory standards and providing high-quality data.

With the advent of new technologies, such as CRISPR and advanced imaging techniques, in vivo studies have become more sophisticated and capable of providing deeper insights into disease mechanisms and treatment effects. This has led to an increased reliance on CROs that possess the necessary infrastructure and expertise to conduct these cutting-edge studies. The growing trend of precision medicine, which requires extensive in vivo research to develop targeted therapies, is also boosting the market growth.

The industry is classified into animal model, service, drug type, therapeutic area, end use, and region.

Based on service, the in vivo CRO market size from the toxicity studies segment is anticipated to witness substantial growth through 2032. Regulatory authorities require comprehensive toxicity data before approving any new pharmaceutical products, making toxicity studies an essential part of the drug development process. In vivo CROs offer specialized expertise and advanced facilities to conduct these complex studies while adhering to stringent regulatory guidelines and providing reliable data.

In vivo CRO market from the clinical pharmacology segment is anticipated to observe a significant CAGR between 2024 - 2032. This is due to its cruciality in understanding the pharmacokinetics and pharmacodynamics of new drug candidates, which are crucial for determining their safety, efficacy, and optimal dosing regimens. In vivo CROs specializing in clinical pharmacology offer advanced capabilities to conduct thorough and precise studies, including absorption, distribution, metabolism, and excretion (ADME) analysis.

Asia Pacific in vivo CRO industry will record impressive growth over 2024-2032 attributed to the expanding pharmaceutical and biotechnology sectors, bolstered by significant investments in R&D activities. The increasing prevalence of chronic diseases is accelerating the need for new therapeutic solutions, thereby driving the demand for in vivo CRO services. The presence of advanced infrastructure and the adoption of innovative technologies will further boost the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing outsourcing by pharmaceutical and biotechnology companies
  - 3.2.1.2 Stringent regulatory landscape for drug approvals
  - 3.2.1.3 Focus on specialized services by CRO's
  - 3.2.1.4 Rising demand for personalized medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Intellectual property rights issues
  - 3.2.2.2 Stringent regulatory policies for animal model use
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Model, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Rodent-based
- 5.2.1 Rat models
- 5.2.2 Mice models
- 5.2.3 Other rodent models
5.3 Non-rodent-based

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Bioanalysis & DMPK studies
6.3 Toxicity studies
- 6.3.1 GLP toxicology studies
- 6.3.2 Non-GLP toxicology studies
6.4 Other services

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Small-molecule drugs
7.3 Large-molecule drugs
- 7.3.1 Cell & gene therapy
- 7.3.2 RNA therapy
- 7.3.3 Other large molecule drugs

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Oncology
8.3 Clinical pharmacology
8.4 Cardiology
8.5 Infectious diseases
8.6 Neurology
8.7 Gastroenterology & hepatology
8.8 Metabolic & endocrine
8.9 Ophthalmology
8.10 Autoimmune / inflammatory conditions
8.11 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 Pharmaceutical & bio pharmaceutical companies
9.3 Medical device companies
9.4 Academic & research institutes

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa